

## INF $\alpha$ induction

Reagent	Final concentration in cell culture	Stock conc	Vendor/provider
SLE-IgG from anti-snRNP+ serum	100 ug/ml	18,3 mg/ml (-80C)	Pfizer
Apoptotic U937	1 mill cells/ml	40 mill cells/ml (-80C)	Pfizer
R848	100 ng/ml	1 mg/ml, -20C	Enzo 420-038-M025
CpG-A ODN2216	0,25 ug/ml	303 ug/ml, -20C	InVivogen tlr1-2216
Pan IFN $\alpha$ ELISA kit			MabTech 3425-1A-20

### Flow cytometry:

Marker	Fluorochrome	Vendor	Catalogue number	dilution
CD3	FITC	Biolegend	300406	1:25
CD303	PE	Miltenyi	130-090-511	1:10
HLA-DR	PerCP	Biolegend	307628	1:50
CD16	PECy7	Biolegend	302016	1:1667
CD86	AF647	Biolegend	305416	1:167
CD56	AF700	BD	557919	1:100
CD14	APCCy7	BD	557831	1:200
CD11c	BV421	Biolegend	562561	1:50
Aqua live/dead		InVitrogen	L34957	1:1000

Cell culture medium: RPMI, 1% PEST, 1% L-glutamine, 10% heat inactivated FCS

Ficoll-Paque PLUS GE Healthcare, #17-1440-03

BD stabilizing fixative #339860

Flow cytometry staining buffer: PBS + 0,05% FCS

### Procedure:

1. Isolate PBMC from fresh sodium heparinized blood by Ficoll Paque separation
2. Stain 1 mill cells for FACS analysis
3. Dilute cells to  $5 \times 10^6$  cells/ml in cell culture medium
4. Plate the cells in 96 well U-bottomed wells, 100  $\mu$ l/well, triplicates
5. Add probes in triplicate in 50  $\mu$ l/well (4x final concentration, diluted in medium) and incubate 30 min at 37C. Add 50  $\mu$ l medium to wells without probe.
6. Add SLE-IgG mixed with U937 in 50  $\mu$ l/well (4x final concentration, diluted in medium) making the total volume per well 200  $\mu$ l. Include R848 and ODN2216 (without probe) as positive controls. Add 50  $\mu$ l medium to wells without stimulus.
7. Add PBS to outer wells
8. Incubate 24h 37C

9. Collect supernatants
10. Freeze the supernatants at -20C until analysis of IFN $\alpha$  concentration using ELISA